Insmed (INSM) Stock Forecast & Price Target

Insmed is supported by a rare combination of already-commercialized assets and a deep respiratory pipeline, led by BRINSUPRI, the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis and the first approved DPP1 inhibitor. Its launch has been exceptional, with $400.1M in 3Q26 revenue, $1.35B-$1.4B guided for 2026, and more than $1B generated within its first four full quarters, while ARIKAYCE added $124.4M in 3Q26 and has a January 28, 2027 PDUFA that could expand its addressable U.S. population from about 15K to over 100K patients. The outlook is further strengthened by TPIP’s four Phase 3 trials and a broader portfolio that could drive cash-flow positivity in 2027 without new capital, supporting combined peak sales guidance above $14B.

Insmed is facing a weaker fundamental setup because four TPIP Phase 3 programs beginning from 2027 drive sharply higher investment before revenue matures, lifting 2027 R&D to $1,022M and SG&A to $1,133M while 2028 opex is modeled $324M higher. Near-term profitability is pressured as 2027E EPS falls to $1.24 from $3.26, operating income declines by $531M, and cost of product revenue rises to 16.8% of sales as Brinsupri’s tiered royalty and outsourced manufacturing weigh on margins. Execution risk also remains elevated across Brinsupri persistence, U.S. and Japan frontline Arikayce launches, payer reset pressure on gross-to-net, and TPIP study complexity, while cash taxes begin in FY27E and cash obligations further limit flexibility.